Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Viren Mehta
With money pouring into biopharma in China, and regulatory reforms favoring market growth and R&D speed, western firms should watch their backs, warns Viren Mehta, founding partner of Mehta Partners LLC.
Buying Shire gives Takeda the chance to exploit global tax benefits and gain other profit-promoting advantages through integrating with Shire's differently focused business. Outside of pharma, business model rationales are changing rapidly, and old certainties cannot be taken for granted. Pharma would ignore the wider revolution at its peril, and Takeda's move is a step in the right direction, argues Viren Mehta, founding partner of Mehta Partners LLC.
President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.
As two high-profile pharma veterans make their move into pharmacy benefit management leadership, Viren Mehta, founding partner of Mehta Partners LLC, ponders the challenges they face and the impact their actions will have on the pharma industry.
It seems only a matter of time that the leaders of established biopharma will need to redefine core functions such as research, manufacturing and marketing around a new vision.
How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.